Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

Isabella C Glitza OlivaMichelle RohlfsNandita Guha-ThakurtaRoland L BassettChantale BernatchezAdi DiabScott E WoodmanCassian YeeRodabe N AmariaSapna P PatelHussein TawbiMichael WongWen-Jen HwuPatrick HwuAmy HeimbergerIan E McCutcheonNicholas PapadopoulosMichael A Davies

Published in: ESMO open (2018)

These results demonstrate that despite their historically dismal prognosis a subset of metastatic melanoma patients with LMD treated with IT IL-2 can achieve long-term survival, but these data need to be verified in a prospective trial setting.

Keyphrases

clinical trial
study protocol
phase ii
randomized controlled trial
cerebrospinal fluid
artificial intelligence